Caribou Biosciences (CRBU) Competitors

AnaptysBio (NASDAQ:ANAB) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, community ranking, media sentiment, risk, profitability and institutional ownership.

Do analysts rate ANAB or CRBU?

AnaptysBio currently has a consensus price target of $41.45, suggesting a potential upside of 131.20%. Caribou Biosciences has a consensus price target of $10.33, suggesting a potential upside of 622.61%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Caribou Biosciences	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is ANAB or CRBU more profitable?

AnaptysBio has a net margin of -289.75% compared to Caribou Biosciences' net margin of -1,290.81%. Caribou Biosciences' return on equity of -45.46% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-289.75%	-287.94%	-37.25%
Caribou Biosciences	-1,290.81%	-45.46%	-38.07%

Which has more risk and volatility, ANAB or CRBU?

AnaptysBio has a beta of -0.02, indicating that its stock price is 102% less volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500.

Does the MarketBeat Community favor ANAB or CRBU?

AnaptysBio received 342 more outperform votes than Caribou Biosciences when rated by MarketBeat users. Likewise, 66.01% of users gave AnaptysBio an outperform vote while only 60.98% of users gave Caribou Biosciences an outperform vote.

Company	Underperform	Outperform
AnaptysBio	Outperform Votes 367 66.01%	Underperform Votes 189 33.99%
Caribou Biosciences	Outperform Votes 25 60.98%	Underperform Votes 16 39.02%

Do insiders & institutionals have more ownership in ANAB or CRBU?

77.5% of Caribou Biosciences shares are held by institutional investors. 33.7% of AnaptysBio shares are held by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has higher earnings and valuation, ANAB or CRBU?

Caribou Biosciences has lower revenue, but higher earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$17.16M	31.80	-$163.62M	-$6.08	-2.95
Caribou Biosciences	$11.48M	11.28	-$102.07M	-$1.65	-0.87

Does the media favor ANAB or CRBU?

In the previous week, Caribou Biosciences had 17 more articles in the media than AnaptysBio. MarketBeat recorded 20 mentions for Caribou Biosciences and 3 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.63 beat Caribou Biosciences' score of 0.16 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caribou Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AnaptysBio and Caribou Biosciences tied by winning 9 of the 18 factors compared between the two stocks.